stockrowSotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Revenue
- +4.36%
- EPS
- +20.1%
- Free cash flow
- +65.0%
- Total debt
- +0.14%
Quarter to September 2026, against a year earlier
Follow SHC
Alert me
Sotera Health Company (SHC) EBITDA
Sotera Health Company's EBITDA for fiscal 2025 was $504.2M, up 7.61% from $468.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $537.0M. Over the past ten years it has ranged from $285.0M (fiscal 2018) to $504.2M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. Sotera Health Company ranks 16th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $504.2M | 7.61% |
| FY2024 | $468.5M | 5.60% |
| FY2023 | $443.7M | 8.42% |
| FY2022 | $409.2M | (1.11%) |
| FY2021 | $413.8M | 14.56% |
| FY2020 | $361.2M | 6.67% |
| FY2019 | $338.6M | 18.80% |
| FY2018 | $285.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $147.7M | 4.14% |
| Jun 2026 | $141.8M | 31.18% |
| Mar 2026 | $108.1M | (22.44%) |
| Dec 2025 | $139.4M | (1.03%) |
| 24 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| QGEN QIAGEN N.V. compare | $651.0M |
| SHC Sotera Health Company | $537.0M |
| RDNT RadNet, Inc. compare | $307.7M |
| CDNA CareDx, Inc. compare | $141.4M |
| VCYT Veracyte, Inc. compare | $123.9M |
| BLLN BillionToOne, Inc. compare | $55.6M |
| NEO NeoGenomics, Inc. compare | $17.5M |
| ADPT Adaptive Biotechnologies Corporation compare | −$22.4M |
| GRAL GRAIL, Inc. compare | −$400.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on SHC
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement